CERo Therapeutics - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi CERO

CERo Therapeutics (CERO) is developing an immune reprogramming system via the CER-T platform to combat tumors. The company is recruiting world-leading engineers to ensure the stability of its scientific core. However, high R&D costs and the risk of side effects create a threat of capital deficiency. The metric reflects current dynamics, while the total EBITDA on the chart demonstrates the asset's real financial power.

CERO Bathi operasional EBITDA CERo Therapeutics Holdings (04.07.2022 - 12.11.2026)

Ringkesan rincian data analitis CERo Therapeutics Holdings (CERO)

- nilai pasar lan prakiraan target analis:

Rega bursa CERo Therapeutics Holdings, Inc.|CERO - Target konsensus

- rincian nilai pasar emiten:

Nilai pasar CERo Therapeutics|CERO - Nilai Perusahaan

- informasi kapitalisasi buku:

Nilai Akuntansi saben Saham CERo Therapeutics|CERO - Kapitalisasi Buku|Koefisien Nilai Pasar marang Nilai Buku cero.bio|CERO - Aset Agregat Perusahaan

- rincian struktur utang lan likuiditas bisnis:

Utang marang Ekuitas CERo Therapeutics|CERO - Utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas CERo Therapeutics Holdings, Inc.|CERO - Gunggung utang perusahaan|Rasio utang marang aset resik CERo Therapeutics|CERO - Utang jangka dawa perusahaan|Tanggungan jangka cendhak CERo Therapeutics|Likuiditas darurat cero.bio

- data bathi lan kelipatan valuasi:

CERO - Bathi resik perusahaan|Prakiraan bathi resik CERo Therapeutics|CERO - Pangali P/E|Rasio prakiraan rega marang bathi CERo Therapeutics Holdings, Inc.|CERO - Pangali rega marang bathi tumrap wutah|Nilai bisnis marang bathi operasional sadurunge panyusutan CERo Therapeutics|CERO - Bathi operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone patang kuartal pungkasan CERo Therapeutics|CERO - Bathi resik saben saham (EPS TTM)|Wutah bathi saben siji saham taun-ka-taun sajrone 12 wulan pungkasan cero.bio|CERO - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep CERo Therapeutics

Pambiji fundamental perusahaan:CERo Therapeutics

Produk sing diprodhuksi CERo Therapeutics Holdings, Inc.

The biopharmaceutical potential of CERo Therapeutics (CERO) in developing non-toxic T-cell technologies requires precise cash flow monitoring to evaluate the effectiveness of R&D investments. By analyzing EBITDA, an investor can discern real operating profit, making it possible to identify dangerous liquidity anomalies that often serve as precursors to deep market corrections and capital drawdowns.

Karo sapa CERo Therapeutics saingan